ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has announced the receipt of a $150,000 cash licensing payment from AiBtl BioPharma Inc., marking a significant milestone in the commercialization of its late-stage drug candidates ABV-1504 and ABV-1505. These candidates, targeting Major Depressive Disorder (MDD) and Attention Deficit Hyperactivity Disorder (ADHD) respectively, have completed Phase II and Phase IIB clinical trials and hold active INDs with the U.S. Food and Drug Administration.

This payment is part of a broader licensing agreement and brings ABVC’s total licensing revenue to $846,000 across strategic partnerships, including deals with ForSeeCon Eye Corporation and OncoX BioPharma, Inc. These partnerships are a testament to ABVC’s capital-efficient, partnership-driven business model and its focus on developing innovative botanical drugs through Phase II/III before licensing them out for global expansion.

Dr. Uttam Patil, ABVC Chief Executive Officer, emphasized the success of the company’s licensing-first strategy, which is designed to generate recurring milestone income and reduce the need for dilutive fundraising. The strategy has already contributed to a 234% increase in annual revenue and a 77% year-over-year improvement in earnings per share, reflecting ABVC’s commitment to creating sustainable long-term value for its shareholders.

The global demand for alternative and effective treatments for CNS disorders is growing, with recent reports highlighting drug shortages affecting hundreds of thousands of patients. ABVC and AiBtl’s progress in botanical drug development offers a timely and legal therapeutic alternative to vulnerable patient populations in need, underscoring the importance of their work in addressing a critical global health challenge.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is ABVC BioPharma Achieves $846K in Licensing Revenue Through Strategic Partnerships.